Mcl-1 and anticancer vaccination: identification of an HLA-A2-restricted epitope

Andersen, Rikke; Wenandy, Lynn; Sørensen, Rikke Bæk; Straten, Per thor; Andersen, Mads Hald

doi:10.1038/sj.leu.2404937

Cited by 6 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the IFN-g ELISPOT we demonstrated that both hematopoetic and solid cancer patients host spontaneous T-cell responses against Mcl-1-derived peptides [42][43][44]. Thus, strong and frequent CTL responses against Mcl-1 were detected in CLL patients, melanoma patients, pancreatic cancer patients and breast cancer patients, whereas no responses could be detected in healthy individuals.…”

Section: Mcl-1mentioning

confidence: 96%

The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens

Straten¹,

Andersen²

2010

Oncotarget

View full text Add to dashboard Cite

AbstrAct:Anti-apoptotic members of the Bcl-2 family (Bcl-2, Bcl-X(L) and Mcl-2) are pivotal regulators of apoptotic cell death. They are all highly overexpressed in cancers of different origin in which they enhance the survival of the cancer cells. Consequently, they represent prime candidates for anti-cancer therapy and specific antisense oligonucleotides or small molecule inhibitors have shown broad anti-cancer activities in pre-clinical models and are currently tested in clinical trials. In addition, immune-mediated tumor destruction is emerging as an interesting modality to treat cancer patients. Notably, spontaneous cellular immune responses against the Bcl-2 family proteins have been identified as frequent features in cancer patients underscoring that these proteins are natural targets for the immune system. Thus, Bcl-2 family may serve as an important and widely applicable target for anti-cancer immunotherapeutic strategies, alone or in the combination with conventional therapy. Here, we summarize the current knowledge of Bcl-2 family proteins as T-cell antigens, which has set the stage for the first explorative trial using these antigens in therapeutic vaccinations against cancer, and discuss future opportunities.

show abstract

Section: Mcl-1mentioning

confidence: 96%

The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens

Straten¹,

Andersen²

2010

Oncotarget

View full text Add to dashboard Cite

show abstract

Section: Prospective Use Of Private Chargers In Res Micro-installatio...mentioning

confidence: 99%

“…Currently, the following wall boxes available on the market enable the implementation of the V1G service: Smappee EV Wall [158], Mye-nergi Zappi V2 [159], Anderson A2 [160], EO Mini PRO 3 [161], ZJ Beny BCP Series [162], Fimer Flexa AC wallbox [163], Ocular IQ Wallbox [164], Enel-x JuiceBox 40 [165] and Tesla Wall Connector [166]. The prices of such chargers range from USD 600 to USD 3000 [158][159][160][161][162][163][164][165][166], while the charging power ranges from 1.4 kW to 7.4 kW (for single-phase AC installation) and from 7.4 kW to 22 kW for three-phase AC installation. (a) the architecture of a prosumer micro-installation using a net-billing system with energy storage and a private charger [114], (b) monthly and daily MEPs from the Polish Power Exchange (in Poland TGE), published by PSE [129,130], (c) typical power demand characteristics with a visible effect flattening (blue arrows) due to the implementation of the V1G concept [167,168,169].…”

Section: Prospective Use Of Private Chargers In Res Micro-installatio...mentioning

confidence: 99%

Sustainable Development of Operational Infrastructure for Electric Vehicles: A Case Study for Poland

et al. 2023

View full text Add to dashboard Cite

This article overviews Poland’s current electric vehicle infrastructure development. It discusses market segmentation and the analysis of charging standards, connectors, and types of charging. The paper focuses on Poland’s charging infrastructure, including costs and charging times for popular electric vehicle models in 2022. It highlights the challenges faced by charging operators and the barriers to infrastructure development. The article also presents the outlook for the electric vehicle market in Poland until 2025 and 2030. Furthermore, it examines private charger development, particularly in prosumer households with renewable energy sources. The implementation of smart charging and the potential for vehicle-to-grid technology in Poland are addressed. Lastly, a comparative analysis of incentives for electric vehicle users in Poland and Norway is discussed in the context of achieving 100% zero-emission vehicle sales by 31 December 2035, in Poland.

show abstract

“…We used peptide-loaded dendritic cell (DC) from a homozygous A/A donor to stimulate autologous peripheral blood mononuclear cell (PBMC) for cloning and establishment of a cytotoxic T lymphocyte (CTL) clone specific for the HER2_P peptide as described earlier. 8 This clone (HER2_P#3) was used to show specific cytotoxic activity against the HER2_P peptide loaded to T2 cells, and importantly, absence of recognition of the HER2_A peptide (Figure 2a). The HLA restriction of the killing was shown by blocking by the HLA class I specific antibody W6/32 ( Figure 2a).…”

mentioning

confidence: 99%

The 1170 A–P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag)

et al. 2009

Self Cite

View full text Add to dashboard Cite

Mcl-1 and anticancer vaccination: identification of an HLA-A2-restricted epitope

Cited by 6 publications

References 11 publications

The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens

The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens

Sustainable Development of Operational Infrastructure for Electric Vehicles: A Case Study for Poland

The 1170 A–P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag)

Contact Info

Product

Resources

About